Research programme: matrix metalloproteinase inhibitors - Johnson & Johnson Pharmaceutical Research and Development, LLC

Drug Profile

Research programme: matrix metalloproteinase inhibitors - Johnson & Johnson Pharmaceutical Research and Development, LLC

Latest Information Update: 18 Dec 2007

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class
  • Mechanism of Action Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer; Cardiovascular disorders

Most Recent Events

  • 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson
  • 04 Jun 2002 This programme is still in active development
  • 26 Jul 2000 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top